Evidence map›Paper›PMID 22650225›Full record

ReviewDiabetes technology & therapeutics2012

Hypoglycemia, diabetes, and cardiovascular disease.

Janet K Snell-Bergeon, R Paul Wadwa

Abstract readReview
In one paragraph

Review in Diabetes technology & therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 2 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Nutraceuticals ofDrug design, development and therapy · 2026
    Review
  11. Glucagon-Like Peptide-1: The Role of Calcium in Gut-Glucose Axis.Advances in experimental medicine and biology · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Janet K Snell-BergeonBarbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Center, Aurora, Colorado 80045, USA. Janet.snell-bergeon@ucdenver.edu
R Paul Wadwa
Colorado School of Public Health · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI ALBERT, RICHARD K · 1985 to 2008
$52.6M
UCHSC DIABETES ENDOCRINOLOGY RESEARCH CENTERP30DK057516 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HUTTON, JOHN C · 2000 to 2010
$14.0M
SUBCLINICAL HEART DISEASE IN INSULIN-DEPENDENT DIABETESR01HL061753 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 1999 to 2007
$5.2M
Complications and Comorbidities of Type 1 DiabetesR01HL113029 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SNELL-BERGEON, JANET KATHLEEN · 2013 to 2016
$2.9M
Determinants of Accelerated CVD in Type 1 DiabetesR01HL079611 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 2004 to 2007
$2.3M
NCRR NIH HHS M01 RR000051NHLBI NIH HHS R01 HL079611NHLBI NIH HHS R01 HL113029NHLBI NIH HHS R01 HL61753NIDDK NIH HHS P30DK57516
6 · The paper itself

Abstract

Cardiovascular disease (CVD) remains the leading cause of death in people with diabetes, and the risk of CVD for adults with diabetes is at least two to four times the risk in adults without diabetes. Complications of diabetes, including not only CVD but also microvascular diseases such as retinopathy and nephropathy, are a major health and financial burden. Diabetes is a disease of glucose intolerance, and so much of the research on complications has focused on the role of hyperglycemia. Clinical trials have clearly demonstrated the role of hyperglycemia in microvascular complications of diabetes, but there appears to be less evidence for as strong of a relationship between hyperglycemia and CVD in people with diabetes. Hypoglycemia has become a more pressing health concern as intensive glycemic control has become the standard of care in diabetes. Clinical trials of intensive glucose lowering in both type 1 and type 2 diabetes populations has resulted in significantly increased hypoglycemia, with no decrease in CVD during the trial period, although several studies have shown a reduction in CVD with extended follow-up. There is evidence that hypoglycemia may adversely affect cardiovascular risk in patients with diabetes, and this is one potential explanation for the lack of CVD prevention in trials of intensive glycemic control. Hypoglycemia causes a cascade of physiologic effects and may induce oxidative stress and cardiac arrhythmias, contribute to sudden cardiac death, and cause ischemic cerebral damage, presenting several potential mechanisms through which acute and chronic episodes of hypoglycemia may increase CVD risk. In this review, we examine the risk factors and prevalence of hypoglycemia in diabetes, review the evidence for an association of both acute and chronic hypoglycemia with CVD in adults with diabetes, and discuss potential mechanisms through which hypoglycemia may adversely affect cardiovascular risk.

Indexed as

AdultAnimalsAtherosclerosisBlood GlucoseCardiovascular DiseasesClinical Trials as TopicDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic AngiopathiesEvidence-Based MedicineFemaleHumansHypoglycemiaMaleMiddle AgedPrevalenceBlood Glucose

Identifiers

PMID22650225
PMCPMC3361183
OpenAlexW2134982098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.